Aromatase inhibitors in malignant diseases of aging.
Aromatase inhibition is an established endocrine treatment modality in postmenopausal breast cancer and is currently considered as an interesting experimental treatment approach in other malignant conditions such as endometrial carcinomas and prostatic cancer. While the 'classic' aromatase inhibitor aminoglutethimide causes many adverse effects that makes it unfit for use in elderly patients, several novel aromatase inhibitors with minimal adverse effects are currently being investigated. These drugs may provide important new tools in the endocrine treatment of malignant diseases in aging patients.
Johannessen
D C
DC
Department of Therapeutic Oncology and Radiophysics, University Hospital of Bergen, Norway.
Lønning
P E
PE
D000367:Age Factors; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D004965:Estrogen Antagonists